Bryan has been a key deputy to Peter Marks, the head of the Center for Biologics Evaluation and Research, as the field of gene and cell therapy field expanded in recent years. His office oversaw the first U.S. approvals of gene therapies for inherited diseases, as well as cell therapies for cancer.
As the field has advanced, the workload for Bryan’s office grew substantially. In 2014, there were fewer than 200 applications to begin human trials of products regulated by the Office of Tissues and Advanced Therapeutics. That number jumped to 666 in 2020 and 556 in 2021, according to a recent presentation by Bryan.
